Harvard School of Public Health
Department of Biostatistics

Cancer Research

Select Publications

Albritton KH, Wiggins CH, Nelson HE, Weeks JC. Site of oncologic specialty care for older adolescents in Utah. J Clin Oncol (in press).

Guha, S., Li, Y., Neuberg, D. (2007) Hidden Markov Modeling of Obscured Spatial Transitional Data with Application to Analysis of Array CGH Data. Journal of the American Statistical Association (in press).

Haddad, R., Crum, C. P., Chen, Z., Krane, J., Burk, R., Li, Y. and Posner, M. (2007) HPV 16 Transmission Between a Couple with HPV Related Head and Neck Cancer. Oral Oncology (in press).

Jackson VA, Mack J, Matsuyama R, Lakoma MD, Sullivan AM, Arnold RM, Weeks JC, Block SD. "The Cat's on the Roof"...and other approaches to discussions at the end of life: A study of oncologists. J Pall Med (in press).

Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky R, Christakis NA. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from CALGB breast and lung cancer trial participants (companion to 9344 and 9730); Med Care (in press).

Mack JW, Co JPT, Goldmann DA, Weeks, JC, Cleary PD. Health care quality for children: The role of health and chronic illness in inpatient care experiences. Arch Ped Adol Med (in press)

Mack JW, Wolfe J, Cook EF, Grier HE, Cleary PD, Weeks JC. Hope and prognostic disclosure. J Clin Oncol (in press).

Mutter GL, Kauderer J, Baak JPA, Alberts DA. Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: A Gynecologic Oncology Group Study. Hum Pathol 2008; (in press).

Yen WF, Kuerer HM, Ottesen RA, Niland JC, Edge SG, Theriault RL, Weeks, JC. Impact of randomized clinical trial results on the use of tamoxifen following breast surgery for ductal carcinoma in situ in the National Comprehensive Cancer Network. J Clin Oncol (in press).


Abel GA, Lee SJ, Weeks JC. Direct-to-Consumer Advertising in oncology: A content analysis of print media. J Clin Oncol 2007; 25:1267-71.

Applebaum KM, Karagas MR, Hunter DJ, Catalano PJ, Byler SH, Morris S, Nelson HN. Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. EHP 2007; 115(8):1231-1236.

Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hurny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thurlimann B, Price KN, Goldhirsch A, Coates AS. Adjuvant chemotherapy followed by Goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients---the International Breast Cancer Study Group Trial VIII. J Clin Oncol 2007; 25(3):263-270.

Betensky, R.A., Louis, D.N. and Cairncross, J.G. (2007). Tests of association under misclassification: Application to histological sampling in oncology. Statistics in Medicine.

Cahill, DP, Levine, KK, Betensky, RA, Codd, PJ, Romany, CA, Batchelor, TT, Futreal, PA, Stratton, MR, Curry, WT, Iafrate, AJ, Louis, DN (2007) Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clincal Cancer Research 13: 2038-2045.

Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, et.al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25(5):486-492.

Cook, A., Gold, D. and Li, Y. (2007) Spatial Clustering Detection for Censored Outcomes. Biometrics, 63: 540-549.

DeSantis, SM, Houseman, EA, Coull, BA, Stemmer-Rachamimov, A, Betensky, RA. A penalized latent class model for ordinal data. Biostatistics. 2007 Jul 11; [Epub ahead of print].

Fukino K, Shen L, Patocs A, Mutter GL, Eng C. Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA 2007; 297(19):2103-2111.

Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB III. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539-1544.

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn H.-J, and Panel Members. Progress and promise: highlights of the International expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133-1144.

Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JAW, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski J. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25:2127-2132.

Karlsson P, Cole BF, Price KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, Murray E, Lindtner J, Collins JP, Holmberg SB, Fey MF, Thurlimann B, Crivellari D, Forbes JF, Gelber RD, Goldhirsch A, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. J Clin Oncol 2007; 25:2019-2026.

Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thurlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Castiglione Gertsch M, Gelber RD, Coates AS, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 2007; 18(4):701-708.

Krzyzanowska MK, Earle CC, Kuntz KM, Weeks JC. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2007; 67:211-8.

Laframboise T, Harrington D, Weir BA. PLASQ: a generalized linear model-based procedure to determine allelic dosage in cancer cells from SNP array data. Biostatistics 2007; 2:323-336.

Li, Y. (2007) Discussion of "Semiparametric regression models with censored data" by Zeng and Lin. Journal of the Royal Statistical Society -Series B, 69: 552-554.

Li, Y., Shih, M. and Betensky, R. (2007) Designed Extension of Survival Studies: Application to Clinical Trials with Unrecognized Heterogeneity. Statistica Sinica, 17:1567-1589.

Li, Y., Tiwari, R., Guha, S. (2007) Mixture cure survival models with dependent censoring. Journal of the Royal Statistical Society B (Statistical Methodology), 69: 285-306.

Litovchick L, Sadasivam S, Florens L, Zhu X, Swanson SK, Velmurugan S, Chen R, Washburn MP, Liu XS, DeCaprio JA (2007). Evolutionally conserved multi-subunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol Cell. 26(4):539-51.

Mack JW, Cook EF, Wolfe J, Grier HE, Cleary PD, Weeks JC. Understanding of prognosis among parents of children with cancer: Parental optimism and the parent-physician interaction. J Clin Oncol 2007; 25:1357-62.

Matthews, AG, Finkelstein, DM, Betensky, RA. (2007). Accounting for age at disease onset in the analysis of familial aggregation of disease. Lifetime Data Analysis 13: 191-209.

Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thurlimann B, Paridaens R, Monnier A, Lang I, Wardley A, Nogaret JM, Gelber R, Castiglione-Gertsch M, Price K, Coates A, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG I-98 trial. Ann Oncol 2007; 18(5):859-867.

Mello M, Joffe S. Compact versus contract: an ethical and legal analysis of industry sponsors' obligations to research subjects. N Engl J Med 2007; 356:2737-43.

Miller, F.G. Joffe, S. Evaluating the therapeutic misconception. Kennedy Inst Ethics J 2007; 16:353-66.

Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB. Results of the Dana-Farber Cancer Institute ALL consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109(3):896-904.

Mutter GL, Zaino RJ, Baak JPA, Bentley RC, Robboy SJ. The Benign Endometrial Hyperplasia Sequence and Endometrial Intraepithelial Neoplasia. Int J Gynecol Pathol 2007; 26:103-114.

Newell M-L, Huang S, Fiore S, Thorne C, Mandelbrot L, Sullivan JL, Maupin R, Delke I, Watts DH, Gelber RD, Cunningham CK. Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. BMC Infectious Diseases 2007, 7:60.

O'Neil J, Tchinda J, Gutierrez A, Moreau L, Maser R, Wong KK, Li W, KcKenna K, Liu XS, Neuberg D, Silverman L, DeAngelo D, Kutok J, Rothstein R, DePinho R, Chin L, Lee C, Look AT. Tandem duplication as a novel mechanism of MYB activation in human T-ALL. Accepted, J Exp Med.

Ozsolak F, Song JS, Liu XS*, Fisher DE* (2007). Global chromatin structure mapping of human promoters. Nat Biotechnol. 25:244-8. *Co-corresponding authors.

Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopasual following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer 2007; 43(11):1646-1653.

Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O’Callaghan CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J Clin Oncol 2007; 25:4569-4574.

Shen L, Catalano PJ, Benson AB, O’Dwyer P, Hamilton SR, Issa JPJ. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Cancer Res 2007; 13(20):6093-6098.

Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, et al. Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007; 369:29-36.

Stewart FM, Wasserman R, Bloomfield C, Petersdorf S, Witherspoon R, Appelbaum F, Ziskind A, McKenna B, Dodson J, Weeks J, Vaughn W, Storer B, Perkel S, Waldinger M. Benchmarks in clinical productivity: an NCCN survey. J Onc Prac 2007; 3:2-8.

Steyerberg E, Neville N, Weeks JC, Earle CC. Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population- based analysis of elderly patients. J Clin Oncol 2007; 25:2389-96.

Sutter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JGM, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25:3859-3865.

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thurlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Prognostice and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG I-98. J Clin Oncol 2007; 25:3846-3852.

Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Chinnaiyan AM, Pienta KJ, Brown M. A hierarchical network of transcription factors governs androgen receptor dependent prostate cancer growth (2007). Mol Cell. 27(3):380-92.


Barbeau, E., Li, Y., Calderon P, Hartman C, Quinn M, Markkanen P, Roelofs C, Frazier L, Levenstein C. (2006) Results of a union-based smoking cessation intervention for apprentice iron workers. Cancer Causes & Control, 17: 53-61.

Berman JJ, bores-Saavedra J, Bostwick D, DeLellis R, Eble J, Hamilton SR, Hruban RH, Mutter GL, Page D, Rohan T, Travis W, Henson DE. Precancer: A conceptual working definition Results of a Consensus Conference. Cancer Detect Prev 2006; 30:387-394.

Buchholz TA, Theriault RL, Niland JC, Hughes ME, Ottesen R, Edge SB, Bookman AM, Weeks JC. The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network centers. J Clin Oncol 2006; 24:361-9.

Carroll JS, Meyer CA, Song J, Li W, Brodsky AS, Hall G, Geistlinger TR, Eeckhoute J, Wang QB, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS*, Brown M* (2006). Genome wide analysis of estrogen receptor binding sites. Nat Genet. 38(11):1289-97. *Co-corresponding authors.

Christian CK, Niland JC, Edge SB, Ottesen RA, Hughes ME, Theriault R, Wilson J, Hergrueter CA, Weeks JC. A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: A study of the National Comprehensive Cancer Network. Ann Surg 2006; 243: 241-9.

Coull, B.A., Houseman, E.A. and Betensky, R.A. (2006). A computationally e±cient multivariate random e®ects model for clustered binary data. Biometrika 93: 587-599. Engler, DA, Mohapatra, G, Louis, DN, Betensky, RA (2006). A pseudolikelihood approach for simultaneous analysis of array comparative genomic hybridizations (aCGH). Biostatistics 7: 399-421.

Fitzmaurice GM, Lipsitz SR, Ibrahim JG, Gelber R, Lipshultz S. Estimation in regression models for longitudinal binary data with outcome-dependent follow-up. Biostatistics 2006; 7(3):469-485.

Giantonio BJ, Levy DE, O’Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB 3rd. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006; 17(9):1399-1403.

Gilbert, J., Li, Y., Pinto, H., Jennings, T., Kies, M., Silverman, P. and Forastiere, A. (2006) Phase II Trial of Taxol in Salivary Gland Malignancies (E1394): A Trial of the Eastern Cooperative Oncology Group. Head and Neck, 28:197 - 204.

Goguen, L. A., Posner, M. R., Tishler, R. Wirth, L. J., Annino, D. J.MD, Sullivan, C. Li, Y., Haddad, R. (2006) Examining the Need for Neck Dissection In the Era of Chemoradiation Therapy for Advanced Head and Neck Cancer. Archives of Otolaryngology - Head & Neck Surgery, 132: 526-531.

Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thurlimann B, Senn H-J (on behalf of St. Gallen Panel Members). First---select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006; 17:1772-1776.

Goodman, M., Li, Y., Bennett, G., Emmons, K., Stoddard, S. (2006) An Optimal Evaluation of Multiple Behavioral Risk Factors for Cancer in a Working Class, Multi-Ethnic Population. Journal of Data Science, 4: 291-306.

Haddad, R.I., Tishler, R., Wirth, L., Norris, C., Goguen, L., Sullivan, C., O'Donnell, L., Li Y, and Posner, M.R. (2006) Rate Of Complete Pathological Responses To Docetaxel/Cisplatin/5-Fluorouracil (TPF) In- duction Chemotherapy In Patients With Newly Diagnosed, Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (SCCHN). Archives of Otolaryngology - Head & Neck Surgery, 132: 678-681.

Hecht JL, Mutter GL. Molecular and Pathologic Aspects of Endometrial Carcinogenesis. J Clin Oncol 2006; 24(29):4783-4791.

Houseman, EA, Coull, BA, Betensky, RA. (2006) Feature-specific constrained latent class analysis for medium throughput genomic data. Biometrics 9, 1062-1070.

International Breast Cancer Study Group. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol 2006; 24(3):337-344.

International Breast Cancer Study Group. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol 2006; 24(3):370-378.

International Breast Cancer Study Group. Tamoxfien after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: IBCSG Trial 13-93. J Clin Oncol 2006; 24(9):1332-1341.

Jhawer M, Mani S, Lefkopoulou M, Hahn RG, Harris J, Catalano PJ, Haller D. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282. Invest New Drugs 2006; 24:447-454.

Joffe S, Fernandez CV, Pentz RD, Ungar DR, Mathew NA, Turner CW, Alessandri AJ, Woodman CL, Singer DA, Kodish E. Involving Children In Decision-Making About Research Participation. J Pediatr 2006; 149:862-8.

Joffe S, Miller FG. Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol 2006; 24:2987-90.

Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24:1395-403.

Lamont EB, Herndon JE 2nd, Weeks JC, Henderson IC, Earle CC, Schilsky RL, Christakis NA, Cancer and Leukemia Group B. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Nats Cancer Inst 2006; 98:1335-8.

Li, Y. (2006) Random Effects Models. (peer-reviewed book chapter) In: H. Pham, Z. Ying, J. Wu, eds. Springer Handbook of Engineering Statistics, Springer-Verlag, London, 687-704.

Li, Y. and Lin, X. (2006) Semiparametric Normal Transformation Models for Spatially Correlated Survival Data. Journal of the American Statistical Association, 101: 591-603.

Li, Y. and Ryan, L. (2006) Inference on survival data with covariate measurement error - an imputation approach. Scandinavian Journal of Statistics, 33: 169-190.

Lieb JD, Beck S, Bulyk ML, Farnham P, Hattori N, Henikoff S, Liu XS, Okumura K, Shiota K, Ushijima T, Greally M (2006). Applying whole-genome studies of epigenetic regulation to study human disease. Cytogenet. Genome Res. 114(1):1-15.

Mack JW, Wolfe J, Grier HE, Cleary PD, Weeks JC. Communication about prognosis between parents and physicians of children with cancer: Parent preferences and the impact of prognostic information. J Clin Oncol 2006; 24:5265-70.

Malin JL, Ko C, Ayanian JZ, Harrington D, Nerenz DR, Kahn KL, Ganther-Urmie J, Catalano PJ, Zaslavsky AM, Wallace RB, Guadagnoli E, Arora NK, Roudier MD, Ganz PA. Understanding cancer patients’ experience and outcomes: development and pilot study of the Cancer Care Outcomes Research and Surveillance patient survey. Support Care Cancer 2006;14(8):837-848.

Matthews, A.G., Betensky, R.A., ..., Finkelstein, D.M. (2006). Analysis of Co-aggregation of cancer based on registry data. Community Genetics 9: 87-92.

McMahon PM, Zaslavsky AM, Weinstein MC, Kuntz KM, Weeks JC, Gazelle GS. Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis. Med Dec Making 2006; 26:497-511.

Miller KL, Karagas MR, Kraft P, Hunter DJ, Catalano PJ, Byler SH, Nelson HN. XPA, haplotypes, and risk of basal and squamous cell carcinoma. Carcinogenesis 2006; 27(8):1670-1675.

Mizoguchi, M, Betensky, RA, Batchelor, TT, Bernay, DC, Louis, DN, Nutt, CL. (2006). Activation of STAT3, MAPK and AKT in malignant astrocy tic gliomas: correlation with EGFR status, tumor grade and survival. J Neuropathol Exp Neurol. 2006;65(12):1181-8.

Mohapatra, G., Betensky, RA, Miller, ER, Carey, B, Gaumont, LD, Engler, DA, Louis, DN. (2006). Glioma test array for use with formalin-fixed, paraffin-embedded tissue: array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization. Journal of Molecular Diagnostics 8: 268-276.

Mutter GL. Endometrial carcinogenesis: an integrated molecular, histologic, and functional model of a dualistic disease. In: Giordano A, Bovicelli A, Kurman R, editors. Molecular Pathology of Gynecologic Cancer. Totowa, New Jersey: Humana, 2006.

Nelson EA, Walker SR, Li W, Liu XS and Frank DA (2006): Identification of STAT5-dependent gene regulatory elements based on inter-species homology. J Biol Chem. 281(36):26216-24.

Oh WK, Austin C, Manola J, George DJ, Donovan M, Waldron H, Varner J, Orechia J, Katcher E, Nevins A, Wright R, Talcott J, Sellers W, Kantoff PW, Weeks J. Development of an integrated prostate cancer research information system: Prostate CRIS. Clin Genitourinary Onc 2006; 5:61-6.

Orbo A, Rise CE, Mutter GL. Regression of latent endometrial precancers by progestin infiltrated intrauterine device. Cancer Res 2006; 66:5613-5617.

Palomero T, Odom D, O'Neil J, Ferrando AA, Margolin A, Neuberg DS, Winter SS, Larson RS, Li W, Liu XS, Young RA and Look AT (2006). Transcriptional Regulatory Networks Downstream of TAL1/SCL in T-cell Acute Lymphoblastic Leukemia. Blood. 108(3):986-92.

Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A, for the International Breast Cancer Study Group. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17:935-944.

Pierie, JP, Betensky, RA, Choudry, U, Willett, CG, Souba, WW, Ott, MJ. (2006). Outcomes in a series of 103 retroperitoneal sarcomas. Eur J Surg Oncol. 32: 1235-1241.

Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HM. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal early stage breast cancer: A decision analysis. Cancer 2006; 66:56-63.

Punglia RS, Weeks JC, Neville BA, Earle CC. Radiation therapy after mastectomy between 1991 and 1999 in elderly women: response to clinical trial information. J Clin Oncol. 2006; 24:3474-82.

Punglia RS, Weeks JC, Neville BA, Earle, CC. Effect of distance to radiation treatment facility on use of radiation therapy after mastectomy in elderly women. Int J Radiat Onc Biol Phys 2006; 66:56-63.

Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurkula M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. JNCI 2006; 98(21):1571-1581.

Riemenschneider, M., Betensky, RA, Pasedag, SM, Louis, DN (2006). AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Research 66: 5618-5623.

Riemenschneider MJ, Mueller W, Betensky RA, Mohapatra G, Louis DN. (2005). In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with FAK activation. Am J Pathol 167: 1379-1387.

Rousseau, A, Nutt, CL, Betensky, RA, Ligon, KL, Rowitch, DH, Louis, DN (2006). Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: Use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol. 65: 1149-1156.

Scholtens, D and Betensky, RA. (2006) A computationally simple NPML Bivariate Survival Estimator for Efficacy and Safety. LIDA 12: 365-387.

Steyerberg EW, Neville BA, Koppert LB, Lemmens VEPP, Tilanus HW, Coebergh JW, Weeks JC, Earle CC. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006; 24:4277-84.

Swinburn IA, Meyer CA, Liu XS, Silver PA, Brodsky AS (2006). Genomic localization of RNA-binding proteins reveals links between pre-mRNA processing and transcription. Genome Res. 16(7):912-21.

Weber F, Shen L, Fukino K, Patocs A, Mutter GL, Caldes T, Eng C. Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation. Am J Hum Genet 2006; 78(6):961-972.

Wittenberg E, Halpern E, Divi N, Prosser LA, Araki SS, Weeks JC. The effect of age, race and gender on preference scores for hypothetical health states. Quality of Life Research 2006; 15:645-53.

Wong, S., Machtay, M. andLi, Y. (2006) Locally Recurrent, Previously Irradiated Head and Neck Cancer: Concurrent Reirradiation and Chemotherapy or Chemotherapy Alone? Journal of Clinical Oncology, 24: 2653-2658.

Zhang, B., Li, Y. and Betensky, R. (2006) E®ects of unmeasured heterogeneity in the linear transformation model for censored data. Lifetime Data Analysis, 12: 191-203.


Baehring, JM, Androudi, S, Longtine, JJ, Betensky, RA, Sklar, J, Foster, C S, Hochberg, FH. (2005) Analysis of clonal immunoglobulin heavy chain rearrangeme nts in ocular lymphoma. Cancer 104: 591-597.

Bellamy, S., Li, Y., Lin, X. and Ryan, L. (2005) Quantifying the bias asso- ciated with PQL covariate e®ects in cluster-randomized trials. Statistica Sinica, 15: 1015-1032.

Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005; 23:8706-8712.

Betensky, R.A., Nutt, C.L, Batchelor, T.T. and Louis, D.N. (2005). Statistical considerations for immunohistochemistry panel development following gene expression pro¯ling of human cancers. Journal of Molecular Diagnostics 7,: 276-282.

Breast International Group (BIG) 1-98 Collaborative Group (Keshaviah A, Gelber RD, Price KN). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353 (26):2747-2757.

Carroll JS, Liu XS, Brodsky AS, Li W, Szary AJ, Meyer CA, Shao W, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M (2005). Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell. 122(1):33-43.

Chirieac L, Shen L, Catalano P, Issa J-P, Hamilton SR. Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. Am J Surg Path 2005; 29(4):429-436.

Cohen SJ, Dobelbower R, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-c in patients with locally advanced adenocarcinoma of the pancreas: ECOG study E8282. Int J Radiation Oncology Biol Phys 2005; 62(5):1345-1350.

Cole BF, Bonetti M, Zaslavsky AM, Gelber RD. A multistate Markov chain model for longitudinal, categorical quality-of-life data subject to non-ignorable missingness. Stat Med 2005; 24:2317-2334.

Colleoni M, Li S, Gelber RD, Coates AS, Castiglione-Gertsch M, Price KN, Lindtner J, Rudenstam C-M, Crivellari D, Collins J, Pagani O, Simoncini E, Thürlimann B, Murray E, Forbes J, Erzen D, Holmberg SB, Veronesi A, Goldhirsch A, for the International Breast Cancer Study Group. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 2005; 16:716-725.

Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M, Goldhirsch, for the IBCSG. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 2005; 366:1108-1110.

Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam C-M, Lindtner J, Erzen D, Snyder R, Collins J, Fey MF, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates AS, Price K, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: The International Breast Cancer Study Group Experience. J Clin Oncol 2005;23(7):1390-1400.

Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 2005; 23:1736-1750.

Dong, S, Nutt, CL, Betensky, RA, Stemmer-Rachamimov, AO, Denko, NC, Ligon, KL, Rowitch, DH, Louis, DN. (2005). Histology-based expression profiling yields novel prognostic markers in human gliblastoma. JNEN 64: 948-955.

Earle CC, Neville BA, Landrum ME, Souza JE, Weeks JC, Block SD, Grunfeld E, Ayanian JZ. Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care 2005; 17: 505-9.

Elkin EB, Weinstein MC, Kuntz KM, Bunnell CR, Weeks JC. Adjuvant ovarian suppression versus chemotherapy for premenopausal, hormone-responsive breast cancer: Quality of life and efficacy tradeoffs. Breast Cancer Res Treat 2005; 93: 25-34.

Emmons K, Puleo P, Park E, Mertens A, Gritz E, Butterfield R, Weeks JC, Li FP. Peer-delivered smoking counseling for childhood cancer survivors increases smoking cessation: the Partnership for Health Study. J Clin Oncol 2005; 23:6516-23.

Emmons KM, Stoddard AM, Fletcher R, Gutheil C, Gonzalez Suarez E, Lobb R, Weeks J, Bigby JA. Cancer prevention among working-class, multi-ethnic adults: Results of the Healthy Directions Health Centers Study. Am J Public Health 2005; 95:1200-5.

Gibson, M., Li, Y., Murphy, B., Hussain, M. H. DeConti, R. C., Ensley, J., Forastiere, A. A. (2005) A Randomized Phase III Evaluation of Paclitaxel + Cisplatin versus Cisplatin + 5-FU in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 23: 3562-3567.

Gibson, M., Li, Y., Murphy, B., Hussain, M. H. DeConti, R. C., Ensley, J., Forastiere, A. A. (2005) Palliation in incurable head and neck cancers: Chemotherapy? Reply. Journal of Clinical Oncology, 23: 8129-8130.

Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn H-J, and panel members. Meeting Highlights: Internationa Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 2005; 16:1569-1583.

Gruber G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam C-M, Holmberg SB, Lindtner J, Goloub R, Collins J, Crivellari D, Carbone A, Thhrlimann, Simoncini E, Fey MF, Gelber RD, Coates AS, Goldhirsch A. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial. J Clin Oncol 2005; 23:7089-7097.

Haller DG, Catalano PJ, Macdonald JS, O’Rourke MA, Frontiera MS, Jackson DV, Mayer RJ. Phase III study of fluorouracil, leucovorin and levamisole in high-risk stage II and III colon cancer: final report of INT-0089. J Clin Oncol 2005; 23:8671-8678.

Hensley ML, Dowell J, Herndon JE, Winer E, Stark N, Weeks JC, Paskett E. "Economic Outcomes of Breast Cancer Survivorship: CALGB study 79804. Breast Cancer Res Trea 2005; 91: 153-161.

Lamont EB, Herndon JE, Weeks JC, Henderson IC Lilenbaum R, Schilsky RL, Christakis NA for the Cancer and Leukemia Group B. Criterion validity of medicare chemotherapy claims in breast and lung cancer patients from CALGB studies 9344 and 9730. J Natl Canc Inst 2005; 97:1080-3.

Li, Y. and Feng, J. (2005) A Nonparametric Comparison of Conditional Distributions with Nonnegligible Cure Fractions. Lifetime Data Analysis, 11: 367-387.

Lilenbaum RC, Herndon JE 2nd, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks JC, Holland JC, Green MR. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005; 23:190-6.

Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23(12):2629-2636.

Ly, N., Li, Y., Sredl, D., Perkins, D., Finn, P., Weiss, S. and Gold, D. (2005) Early Life Immune Response to Allergens: Does It Predict Elevated IgE Beyond Infancy? Journal of Clinical Immunology, 25: 314-320.

Mack JW, Hilden JM, Watterson J, Grier HE, Weeks JC, Wolfe J. Parent and physician perspectives on quality of care at the end of life in children with cancer. J Clin Oncol 2005; 23:9155-61.

Matthews, A.G., Finkelstein, D.M., Betensky, R.A. (2005) Analysis of familial aggregation in the presence of varying family size. Applied Statistics 54; 847-862.

Nutt, C.L., Betensky, R.A., Brower, M.A., Batchelor, T.T., Louis, D.N. and Stemmer-Rachamimov, A.O. (2005). YKL-40 is a marker for distinguishing hist ological subtypes of high grade gliomas. Clinical Cancer Research 11: 2258-2264.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang C-S, Andersson M, Inbar M, Lichinitser M, Lang I, Ulrike N, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFaddn E, Dolci S, Gelber RD. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16):1659-1672.

Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing adjuvant endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis. J Clin Oncol 2005; 23:5178-87.

Regan MM, Gelber RD. Predicting response to systemic treatments: Learning from the past to plan for the future. The Breast 2005; 14:582-593.

Sargent DJ, Wieand S, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O’Callaghan CJ, Francini G, Grothey A, O’Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23:8664-8670.

Shih, HA, Betensky, RA, Dorfman, MV, Louis, DN, Loeffer, JS, Batchelor, TT (2005). Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiation Oncology Bio Physics 63: 704-710.

Steyerberg EW, Earle CC, Neville BA, Weeks JC. Racial differences in surgical evaluation, treatment, and outcome of locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol 2005; 23:510-7.

Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol 2005; 23(22):4897-4904.

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase-inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619-629.

Wittenberg E, Winer E, Weeks JC. Patient utilities for advanced cancer: effect of current health on values. Med Care 2005; 43: 173-81.

Yu, C., Wang, S., Pan, B., Wu, M., Ho, C., Smith, T., Li, Y. and Christiani, D. (2005) No Association between Residential Exposure to Petrochemicals and Brain Tumor Risk. Cancer Epidemiology, Biomarkers & Prevention, 14(12): 3007-3009.

Yu, C., Wang, S., Pan, B., Wu, M., Ho, C., Smith, T., Li, Y. and Christiani, D. (2005) Residential Exposure to Petrochemicals and Risk of Leukemia: Using GIS Tools to Construct Individual-level Residential Exposure Estimates. American Journal of Epidemiology, 164: 200-207.


Argiris, A., Li, Y., Murphy, B. and Forastiere, A. (2004) Outcome of el- derly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. Journal of Clinical Oncology, 22(2): 262-268.

Argiris, A., Li, Y. and Forastiere, A. (2004) Prognostic factors and long- term survivorship in patients with recurrent or metastatic head and neck can- cer: an analysis of two Eastern Cooperative Oncology Group randomized trials. Cancer, 101: 2222-2229.

Ayanian JZ, Chrischilles EA, Fletcher RH, Fouad MN, Harrington DP, Kahn KL, Kiefe CI, Lipscomb J, Malin JL, Potosky AL, Provenzale DT, Sandler RS, van Ryn M, Wallace RB, Weeks JC, West DW. Understanding cancer treatment and outcomes: The Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium. J Clin Oncol 2004; 22:2992-6.

Bellamy, S., Li, Y., Ryan, L., Lipsitz, S., Jacobson, M. and Wright, R. (2004) Analysis of clustered and interval censored data from a community-based study in asthma. Statistics in Medicine, 23: 3607-3621.

Benson AB, Catalano PJ. A rose, is a rose, is a rose…or not. J Clin Oncol 2004; 22(10):1773-1775.

Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 2004; 5(3):465-81. Joffe S, Harrington DP, George SL, Emanuel EJ, Budzinski LA, Weeks JC. Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis. BMJ. 2004; 328:1463.

Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ. When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Economics 2004;13:429-36.

Devlin, P., Kazakin, J., Adak, S., Li, Y., Noris, C., Clark, J. R., Posner, M. R., and Busse, Paul M. (2004) Prospective Phase II Trial of PFL-Induction Chemotherapy Followed by De¯nitive Local Treatment for Advanced Squamous Cell Carcinoma of the Head and Neck: 10 Year Follow-up. American Journal of Clinical Oncology, 27(4):369-375.

Earle CC, Neville BA, Landrum ME, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004; 22:315-21.

Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol. 2004; 22:854-63.

Joffe S, Harrington DP, George SL, Emanuel EJ, Budzinski LA, Weeks JC. Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis. BMJ 2004; 328:1463-6.

Kotz, T., Costello, R., Li, Y. and Posner, M. (2004) Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head and Neck, 26 (4):365-72.

Langer, C.,Li, Y., Jennings T., DeConti, C., Nair, S., Cohen R., Forastiere A. (2004) Phase II Evaluation of 96-Hour Paclitaxel Infusion in Advanced (Re- current or Metastatic) Squamous Cell Carcinoma of the Head and Neck (E3395): A Trial of the Eastern Cooperative Oncology Group, Cancer Investigation, 22: 823-831.

Li, Y. and Ryan, L. (2004). Survival analysis with heterogeneous measure- ment error. Journal of the American Statistical Association, 99(465): 724-735.

Lipshultz SE, Nader R, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351:145-153.

Megyesi, JF, Kachur, E, Lee, DA, Zlatescu, MC, Betensky, RA, Forsyth, PA, Okada, Y, Sasaki, H, Louis, DN, Cairncross, JG. Imaging correlates of molecular signatures in oligodendroglias. Clinical Cancer Research, 2004; 10:4303-4306.

Meyerhardt JA, Tepper JE, Niedzwieck D, Hollis DR, Schrag D, Ayanian JZ, O'Connell MJ, Weeks JC, Mayer RJ, Willett CG, Macdonald JS, Benson AB, Fuchs CS. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively-resected rectal cancer: Findings from the Intergroup 0114 Study. J Clin Oncol 2004; 22:166-74.

Ng AK, Li S, Neuberg D, Silver B, Weeks J, Mauch P. Factors influencing treatment recommendations in early-stage Hodgkin's disease: a survey of physicians. Annals of Oncology 2004; 15:261-9.

Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet. 2004; 363:263-70.

Plotkin, S.R., Betensky, R.A., Hochberg, F.H., Grossman, S.A., Lesser, G.J., Nabors, L.B., Batchelor, T.T. Treatment of relapsed central nervous system lymphoma with high dose methotrexate. Clinical Cancer Research, 2004; 10: 5643-5646.


Adelstein, D., Li, Y., Adams, G., Wagner, H., Kish, J., Ensley, J., Schuller, D. and Forastiere, A. (2003) A phase III comparison of standard radiation ther- apy (RT) versus RT plus concurrent cisplatin (DDP) versus split-course RT plus concurrent DDP and 5FU in patients with unresectable squamous cell. Journal of Clinical Oncology, 21,:92-98.

International Breast Cancer Study Group. Adjuvant chemotherapy followed by Goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2003; 95:1833-1846.

Crivellari D, Price K, Gelber RD, Castiglione-Gertsch M, Rudenstam C-M, Lindtner J, Fey MF, Senn H-J, Coates AS, Collins J, Goldhirsch. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21 year results of International Breast Cancer Study Group Trial IV. J Clin Oncol 2003; 21:4517-4523.

Davidov O, Zelen M. The theory of case control studies for early detection programs. Biostatistics 2003; 4:441-.421.

Gelber RD, Bonetti M, Castiglione-Gertsch M, Coates AS, Goldhirsch A. for the IBCSG. Tailoring adjuvant treatments for the individual breast cancer patient. The Breast 2003; 12:558-568.

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thhrlimann B, Senn H-J. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21(17):3357-3365.

Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE, Asselin BL. Childhood t-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience. J Clin Oncol 2003; 21(19):3616-3622.

Hinton S, Catalano PJ, Einhorn LH, Nichols CR, Crawford ED, Vogelzang N, Trump D, Loehrer PJ. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors. Cancer 2003; 97:1869-1875.

Johnston PG, Benson III AB, Catalano P, Sambasiva Rao M, O'Dwyer PJ, Allegro CJ. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol, 2003; 21(5):815-819.

Joseph NE, Sigurdson ER, Hanlon AL, Wang H, Mayer RJ, MacDonald JS, Catalano PJ, Haller DG. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol 2003; 10:213-218.

Landry JC, Rosnethal D, Spitz F, Haller D, Benson A, Sigurdson E, Catalano P. ECOG 1297: a phase I study of preoperative radiation therapy (RT) with concurrent protracted continuous infusion 5-FU and dose escalating oxaliplatin followed by surgery, adjuvant 5-FU, and leucovorin for locally advanced (T3/4) rectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2003 Oct 1; 57(2 Suppl): S179.

Leaf AN, Propert K, Corcoran C, Catalano PJ, Trump DL, Harris JE, Davis TE. Phase II study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): and Eastern Cooperative Oncology Group study. Med Oncolo. 2003; 20(2):137-46.

Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup Trial INT-0089. J Clin Oncol 2003; 21(15):2912-2919.

Li, Y. and Lin, X. (2003) Testing random e®ects in uncensored/Censored clustered Data with categorical responses. Biometrics, 59(1): 25-35.

Li, Y. and Lin, X. (2003) Functional inference in frailty measurement error models for clustered survival data using the SIMEX approach. Journal of the American Statistical Association, 98(461): 191-204.

Li, Y., Ryan, L., S., Bellamy, and Satten, G. (2003) Inference on clustered survival data using imputed frailties. Journal of Computational and Graphical Statistics, 12(3):640-662.

Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB 3rd, Macdonald JS, Fuchs CS. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 2003; 98(3):484-495.

Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, Fuchs CS. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003; 21(3):433-440.

Meyerhardt JA, Catalano PJ, Schrag D, Ayanian JZ, Haller DG, Mayer RJ, Macdonald JS, Benson III AB, Fuchs CS. Association of hospital procedure volume and outcomes in patients with colon cancer at high-risk for recurrence. Ann Intern Med 2003; 139: 649-657.

Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, Collins J. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 2003; 21(7):1205-1213.

Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology Technology Assessment Working Group Update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003; 21(13): 2597-2599.


Chen M-H, Harrington DP, Ibrahim JG. Bayesian cure rate models for malignant melanoma: a case-study of Eastern Cooperative Oncology Group Trial E1690. Appl Statist, 2002; 51(2):135-150.

International Breast Cancer Study Group (Richard D. Gelber, Writing Committee). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst, 2002; 94:1054-1065.

Li, Y. and Ryan, L. (2002) Modeling spatial survival data using semi- parametric frailty models. Biometrics, 58: 287-297.

Li, Y., Betensky, R., Louis, D. and Cairncross, J. (2002) The use of frailty hazard models for unrecognized heterogeneity that interacts with treatment: considerations of e±ciency and power. Biometrics, 58(1): 232-236.


Braustein, A., Li, Y., Hirschland, D. and Edington, D. (2001) Internal associations among Health-risk Factors and Risk Prevalence. American Journal of Health Behavior, 25(4):407-417.

Berbeau, E., Li, Y., Emmons, K., Youngstrom, R. and Sorensen, G. (2001) Working with Taft-Hartley funds to promote smoking cessation among union- ized works. American Journal of Public Health, 91: 1412-1415.

Colevas, A., Adak, S., Tishler, B., Busse, P. Li, Y., Posner, M. (2001) Hypothyroidism Incidence Following Multi-Modality Treatment for Stage III & IV Squamous Cell Carcinomas of the Head and Neck. International Journal of Radiation Oncology, Biology and Physics, 51: 599-604.

Martin, K.J., Graner, E., Li, Y., et al. (2001) Array analysis of gene ex- pression for the early detection of disseminated breast tumor cells. PNAS, 98(5):2646-51.

Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. High-Dose Interferon Alfa-2b Significantly Prolonged Relapse-Free and Overall Survival Compared with the GM2-KLH/QS-21 Vaccine in Patients with Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801, Journal of Clinical Oncology, 2001; 19:2370-2380.

Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer for early detection clinical trials: mammograms and physical examinations. J Clin Oncol, 2001; 19(15):3490-3499.


Li, Y. and Lin, X. (2000) Covariate measurement errors in frailty models for clustered survival data. Biometrika, 87(4):849-66.


Gray RJ. A Bayesian analysis of institutional effects in a multicenter cancer clinical trial. Biometrics, 1994, 50:244-253.


Gelman RS. Keeping an open mind about the doses of chemotherapy. JNCI, 1990; 82(18):1446-1448.